NewAmsterdam Pharma Company N.V. (NAMS) Income Statement
NAMS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNAMS revenue and net income
Where NAMS's revenue goes
2025Each bar shows an amount and its share of revenue. NAMS kept −905.7% of revenue as net income.
NAMS profit margins
NAMS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −50.6% | — | — | — |
| Gross profit | −50.7% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NAMS quarterly EPS vs estimates
NewAmsterdam Pharma beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.50).
NAMS income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $22.5M | $45.6M |
| Cost of revenue | $59,000 | $113,000 |
| Gross profit | $22.4M | $45.6M |
| Research & development | $141.8M | $151.4M |
| Sales, general & admin | $106.3M | $70.4M |
| Total operating expenses | $248.1M | $221.9M |
| Operating income | −$225.7M | −$176.3M |
| Interest income | $27.6M | $16.9M |
| Interest expense | — | $0 |
| Income before taxes | −$203.8M | −$241.6M |
| Income taxes | — | −$1,000 |
| Net income | −$203.8M | −$241.6M |
| EBITDA | −$242.3M | −$241.5M |
| EPS (diluted) | −$1.47 | −$2.46 |
| Gross margin | 99.7% | 100.0% |
| Operating margin | −1,002.9% | −386.9% |
| Net margin | −905.7% | −530.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '22 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $32,000 | $348,000 | $19.1M | $3.0M | $12.8M | $5.5M |
| Cost of revenue | $0 | $500,000 | $59,000 | $64,000 | $45,000 | $0 | $51,000 | $0 |
| Gross profit | $3.7M | $2.5M | −$27,000 | $348,000 | $19.1M | $3.0M | $12.8M | $5.5M |
| Research & development | $41.7M | $37.5M | $38.6M | $31.0M | $27.5M | $44.8M | $34.9M | $28.4M |
| Sales, general & admin | $26.9M | $23.4M | $27.4M | $24.5M | $27.3M | $27.2M | $35.5M | $5.2M |
| Total operating expenses | $68.6M | $61.0M | $66.0M | $55.5M | $54.8M | $71.9M | $56.0M | $33.6M |
| Operating income | −$64.9M | −$58.4M | −$66.0M | −$55.1M | −$35.6M | −$68.9M | −$43.2M | −$28.1M |
| Interest income | $5.8M | $5.7M | $6.5M | $6.7M | $7.1M | $7.4M | $4.5M | — |
| Interest expense | — | — | — | — | — | — | $3.2M | — |
| Income before taxes | −$64.1M | −$48.4M | −$74.9M | −$72.0M | −$17.4M | −$39.5M | −$92.2M | −$38.0M |
| Net income | −$64.1M | −$48.4M | −$74.9M | −$72.0M | −$17.4M | −$39.5M | −$92.2M | −$38.0M |
| EBITDA | −$59.7M | −$48.4M | −$74.9M | −$71.9M | −$17.3M | −$39.5M | −$111.7M | −$38.0M |
| EPS (diluted) | −$0.52 | −$0.34 | −$0.63 | −$0.41 | −$0.13 | −$0.30 | −$0.93 | −$0.27 |
| Gross margin | 100.0% | 83.6% | −84.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −1,752.6% | −1,921.7% | −206,187.5% | −15,845.7% | −186.1% | −2,314.5% | −338.5% | −509.9% |
| Net margin | −1,732.9% | −1,593.5% | −234,134.4% | −20,691.1% | −90.7% | −1,327.3% | −721.7% | −691.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NAMS's financial statements (latest annual report filed February 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NAMS financial results
In fiscal year 2025 (ended December 31, 2025), NewAmsterdam Pharma reported revenue of $22.5 million, down 50.6% from the year before. It had a net loss of $203.8 million, a net profit margin of −905.7%. Diluted earnings per share came to −$1.47.
See the NAMS stock overview for the latest quote and news, or the NAMS chart for price history and technical indicators.
NAMS income statement FAQ
What is NewAmsterdam Pharma's annual revenue?
NewAmsterdam Pharma reported total revenue of $22.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 50.6% from $45.6 million the previous year.
Is NewAmsterdam Pharma profitable?
No. NewAmsterdam Pharma reported a net loss of $203.8 million in fiscal 2025, a net profit margin of −905.7%; its operating margin was −1,002.9%.
What is NewAmsterdam Pharma's gross margin?
NewAmsterdam Pharma's gross margin was 99.7% in fiscal 2025: for every $100 of revenue, NewAmsterdam Pharma kept $100 after the direct cost of its products and services.
How much does NewAmsterdam Pharma spend on research and development?
NewAmsterdam Pharma spent $141.8 million on research and development in fiscal 2025, 630.3% of revenue.
What are NewAmsterdam Pharma's earnings per share?
NewAmsterdam Pharma earned $-1.47 per diluted share in fiscal 2025, compared with $-2.46 a year earlier.
When will NewAmsterdam Pharma report its next earnings?
NewAmsterdam Pharma is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens.
When does NewAmsterdam Pharma's fiscal year end?
NewAmsterdam Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 18, 2026.